Vascular Inflammation and Cholesterol Lowering Therapy

Rigshospitalet

Status and phase: Withdrawn; Phase 4

Conditions: Lipid Lowering, Vascular Inflammation

Treatments: Drug: Evolocumab or Alirocumab

Study type: Interventional

Funder types: Other

Identifiers

NCT02941016

0002

Details and patient eligibility

About

This study aim to detect change in vascular inflammation following intense lipid lowering therapy

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• treatment with PCSK-9 inhibitors

Exclusion criteria

• Infection Pregnancy Severe claustrophobia Weight >140 kg

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Lipid lowering

Experimental group

Treatment:

Drug: Evolocumab or Alirocumab